Polyamine transport as a target for treatment of Pneumocystis pneumonia

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 12, 2009, Pages 5259-5264

  Liao, Chung Ping ^a   Phanstiel IV, Otto ^b   Lasbury, Mark E ^a   Zhang, Chen ^a   Shao, Shoujin ^a,c   Durant, Pamela J ^a   Cheng, Bi Hua ^d   Lee, Chao Hung ^a,e  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CENTRAL FLORIDA   (United States)

^c BEIJING HOSPITAL   (China)

^d CHANG GUNG UNIVERSITY   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

N (4 AMINO BUTYL) N' (10 [[4 (4 AMINOBUTYLAMINO)BUTYLAMINO]METHYL]ANTHRACEN 9 YLMETHYL)BUTANE 1,4 DIAMINE; N (4 AMINO BUTYL) N' (4 [[4 (4 AMINO BUTYLAMINO)BUTYLAMINO]METHYL]BENZYL)BUTANE 1,4 DIAMINE; N (4 AMINOBUTYL) N ANTHRACEN 9 YLMETHYLBUTANE 1,4 DIAMINE; N [4 (4 AMINOBUTYLAMINO)BUTYL] N ANTHRACEN 9 YLMETHYLBUTANE 1,4 DIAMINE; N1 ANTHRACEN 9 YLMETHYL BUTANE 1,4 DIAMINE; POLYAMINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROL GROUP; CONTROLLED STUDY; CYTOTOXICITY; DISEASE SEVERITY; DRUG EFFECT; DRUG STRUCTURE; DRUG TRANSPORT; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LUNG ALVEOLUS MACROPHAGE; NONHUMAN; PATHOLOGY; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT; SURVIVAL RATE; TREATMENT DURATION;

ANIMALS; ANTHRACENES; ANTIFUNGAL AGENTS; APOPTOSIS; BENZENE; BIOLOGICAL TRANSPORT; FEMALE; INJECTIONS, INTRAMUSCULAR; MACROPHAGES, ALVEOLAR; MOLECULAR STRUCTURE; PNEUMOCYSTIS CARINII; PNEUMONIA, PNEUMOCYSTIS; POLYAMINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 71249130797     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00662-09     Document Type: Article

References (47)

1. Aziz, S. M., M. P. Gosland, P. A. Crooks, J. W. Olson, and M. N. Gillespie. 1995. A novel polymeric spermine conjugate inhibits polyamine transport in pulmonary artery smooth muscle cells. J. Pharmacol. Exp. Ther. 274:181-186.
2. Bacchi, C. J., H. C. Nathan, S. H. Hutner, P. P. McCann, and A. Sjoerdsma. 1980. Polyamine metabolism: a potential therapeutic target in trypanosomes. Science 210:332-334.
3. Bacchi, C. J., and N. Yarlett. 2002. Polyamine metabolism as chemotherapeutic target in protozoan parasites. Mini Rev. Med. Chem. 2:553-563.
4. Bartlett, M. S., J. A. Fishman, S. F. Queener, M. M. Durkin, M. A. Jay, and J. W. Smith. 1988. New rat model of Pneumocystis carinii infection. J. Clin. Microbiol. 26:1100-1102.
5. Burns, M. R., G. F. Graminski, R. S. Weeks, Y. Chen, and T. G. O'Brien. 2009. Lipophilic lysine-spermine conjugates are potent polyamine transport inhibitors for use in combination with a polyamine biosynthesis inhibitor. J. Med. Chem. 52:1983-1993.
6. Carrillo, C., S. Cejas, M. Cortes, C. Ceriani, A. Huber, N. S. Gonzalez, and I. D. Algranati. 2000. Sensitivity of trypanosomatid protozoa to DFMO and metabolic turnover of ornithine decarboxylase. Biochem. Biophys. Res. Commun. 279:663-668.
7. Chen, Y., R. S. Weeks, M. R. Burns, D. W. Boorman, A. Klein-Szanto, and T. G. O'Brien. 2006. Combination therapy with 2-difluoromethylornithine and a polyamine transport inhibitor against murine squamous cell carcinoma. Int. J. Cancer 118:2344-2349.
8. Clarkson, A. B., Jr., M. Saric, and R. W. Grady. 1990. Deferoxamine and eflornithine (DL-α-difluoromethylornithine) in a rat model of Pneumocystis carinii pneumonia. Antimicrob. Agents Chemother. 34:1833-1835.
9. Clarkson, A. B., Jr., D. E. Williams, and C. Rosenberg. 1988. Efficacy of DL-α-difluoromethylornithine in a rat model of Pneumocystis carinii pneumonia. Antimicrob. Agents Chemother. 32:1158-1163.
10. Covassin, L., M. Desjardins, D. Soulet, R. Charest-Gaudreault, M. Audette, and R. Poulin. 2003. Xylylated dimers of putrescine and polyamines: influence of the polyamine backbone on spermidine transport inhibition. Bioorg. Med. Chem. Lett. 13:3267-3271.
11. Cushion, M. T., D. Stanforth, M. J. Linke, and P. D. Walzer. 1985. Method of testing the susceptibility of Pneumocystis carinii to antimicrobial agents in vitro. Antimicrob. Agents Chemother. 28:796-801.
12. Gerner, E. W., and F. L. Meyskens, Jr. 2004. Polyamines and cancer: old molecules, new understanding. Nat. Rev. Cancer 4:781-792.
13. Gillin, F. D., D. S. Reiner, and P. P. McCann. 1984. Inhibition of growth of Giardia lamblia by difluoromethylornithine, a specific inhibitor of polyamine biosynthesis. J. Protozool. 31:161-163.
14. Gilman, T. M., Y. J. Paulson, C. T. Boylen, P. N. Heseltine, and O. P. Sharma. 1986. Eflornithine treatment of Pneumocystis carinii pneumonia in AIDS. JAMA 256:2197-2198.
15. Graminski, G. F., C. L. Carlson, J. R. Ziemer, F. Cai, N. M. Vermeulen, S. M. Vanderwerf, and M. R. Burns. 2002. Synthesis of bis-spermine dimers that are potent polyamine transport inhibitors. Bioorg. Med. Chem. Lett. 12:35-40.
16. Hanson, W. L., M. M. Bradford, W. L. Chapman, Jr., V. B. Waits, P. P. McCann, and A. Sjoerdsma. 1982. α-Difluoromethylornithine: a promising lead for preventive chemotherapy for coccidiosis. Am. J. Vet. Res. 43:1651-1653.
17. Heston, W. D., D. Kadmon, D. F. Covey, and W. R. Fair. 1984. Differential effect of α-difluoromethylornithine on the in vivo uptake of 14C-labeled polyamines and methylglyoxal bis(guanylhydrazone) by a rat prostate-derived tumor. Cancer Res. 44:1034-1040.
18. Huang, L., K. Crothers, C. Atzori, T. Benfield, R. Miller, M. Rabodonirina, and J. Helweg-Larsen. 2004. Dihydropteroate synthase gene mutations in Pneumocystis and sulfa resistance. Emerg. Infect. Dis. 10:1721-1728.
19. Huber, M., J. G. Pelletier, K. Torossian, P. Dionne, I. Gamache, R. Charest-Gaudreault, M. Audette, and R. Poulin. 1996. 2,2′-Dithiobis(N- ethyl-spermine-5-carboxamide) is a high affinity, membrane-impermeant antagonist of the mammalian polyamine transport system. J. Biol. Chem. 271:27556-27563.
20. Igarashi, K., and K. Kashiwagi. 2000. Polyamines: mysterious modulators of cellular functions. Biochem. Biophys. Res. Commun. 271:559-564.
21. Kaur, N., J. G. Delcros, J. Imran, A. Khaled, M. Chehtane, N. Tschammer, B. Martin, and O. Phanstiel IV. 2008. A comparison of chloroambucil- and xylene-containing polyamines leads to improved ligands for accessing the polyamine transport system. J. Med. Chem. 51:1393-1401.
22. Lasbury, M. E., P. J. Durant, C. A. Ray, D. Tschang, R. Schwendener, and C. H. Lee. 2006. Suppression of alveolar macrophage apoptosis prolongs survival of rats and mice with Pneumocystis pneumonia. J. Immunol. 176:6443-6453.
23. Lasbury, M. E., S. Merali, P. J. Durant, D. Tschang, C. A. Ray, and C. H. Lee. 2007. Polyamine-mediated apoptosis of alveolar macrophages during Pneumocystis pneumonia. J. Biol. Chem. 282:11009-11020.
24. Levin, V. A., K. R. Hess, A. Choucair, P. J. Flynn, K. A. Jaeckle, A. P. Kyritsis, W. K. Yung, M. D. Prados, J. M. Bruner, S. Ictech, M. J. Gleason, and H. W. Kim. 2003. Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin. Cancer Res. 9:981-990.
25. Liao, C. P., M. E. Lasbury, S. H. Wang, C. Zhang, P. J. Durant, Y. Murakami, S. Matsufuji, and C. H. Lee. 2009. Pneumocystis mediates overexpression of antizyme inhibitor resulting in increased polyamine levels and apoptosis in alveolar macrophages. J. Biol. Chem. 284:8174-8184.
26. Luk, G. D., G. Goodwin, L. J. Marton, and S. B. Baylin. 1981. Polyamines are necessary for the survival of human small-cell lung carcinoma in culture. Proc. Natl. Acad. Sci. USA 78:2355-2358.
27. Merali, S. 1999. Pneumocystis carinii polyamine catabolism. J. Biol. Chem. 274:21017-21022.
28. Meshnick, S. R. 1999. Drug-resistant Pneumocystis carinii. Lancet 354:1318-1319.
29. Milord, F., J. Pepin, L. Loko, L. Ethier, and B. Mpia. 1992. Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness. Lancet 340:652-655.
30. Müller, I. B., R. Das Gupta, K. Luersen, C. Wrenger, and R. D. Walter. 2008. Assessing the polyamine metabolism of Plasmodium falciparum as chemotherapeutic target. Mol. Biochem. Parasitol. 160:1-7.
31. O'Shaughnessy, J. A., L. M. Demers, S. E. Jones, J. Arseneau, P. Khandelwal, T. George, R. Gersh, D. Mauger, and A. Manni. 1999. Alpha-difluoromethylornithine as treatment for metastatic breast cancer patients. Clin. Cancer Res. 5:3438-3444.
32. Paulson, Y. J., T. M. Gilman, P. N. Heseltine, O. P. Sharma, and C. T. Boylen. 1992. Eflornithine treatment of refractory Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. Chest 101:67-74.
33. Phanstiel, O., IV, N. Kaur, and J. G. Delcros. 2007. Structure-activity investigations of polyamine-anthracene conjugates and their uptake via the polyamine transporter. Amino Acids 33:305-313.
34. Roy, U. K., N. S. Rial, K. L. Kachel, and E. W. Gerner. 2008. Activated K-RAS increases polyamine uptake in human colon cancer cells through modulation of caveolar endocytosis. Mol. Carcinog. 47:538-553.
35. Rudmann, D. G., A. M. Preston, M. W. Moore, and J. M. Beck. 1998. Susceptibility to Pneumocystis carinii in mice is dependent on simultaneous deletion of IFN-gamma and type 1 and 2 TNF receptor genes. J. Immunol. 161:360-366.
36. Sahai, J., and A. J. Berry. 1989. Eflornithine for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome: a preliminary review. Pharmacotherapy 9:29-33.
37. Slatore, C. G., and S. A. Tilles. 2004. Sulfonamide hypersensitivity. Immunol. Allergy Clin. N. Am. 24:477-490, vii.
38. Smego, R. A., Jr., S. Nagar, B. Maloba, and M. Popara. 2001. A meta-analysis of salvage therapy for Pneumocystis carinii pneumonia. Arch. Intern. Med. 161:1529-1533.
39. Smith, D. E., S. Davies, J. Smithson, I. Harding, and B. G. Gazzard. 1992. Eflornithine versus cotrimoxazole in the treatment of Pneumocystis carinii pneumonia in AIDS patients. AIDS 6:1489-1493.
40. Thomas, C. F., Jr., and A. H. Limper. 2007. Current insights into the biology and pathogenesis of Pneumocystis pneumonia. Nat. Rev. Microbiol. 5:298-308.
41. Valerio, A., E. Tronconi, F. Mazza, A. Cargnel, G. Fantoni, and C. Atzori. 2006. DHPS-mutated isolates of Pneumocystis jirovecii from HIV-infected individuals: analysis of related ITS genotypes. J. Eukaryot. Microbiol. 53(Suppl. 1):S108-S109.
42. Vlastos, A. T., L. A. West, E. N. Atkinson, I. Boiko, A. Malpica, W. K. Hong, and M. Follen. 2005. Results of a phase II double-blinded randomized clinical trial of difluoromethylornithine for cervical intraepithelial neoplasia grades 2 to 3. Clin. Cancer Res. 11:390-396.
43. Wang, C., J. G. Delcros, J. Biggerstaff, and O. Phanstiel, IV. 2003. Molecular requirements for targeting the polyamine transport system. Synthesis and biological evaluation of polyamine-anthracene conjugates. J. Med. Chem. 46:2672-2682.
44. Wang, C., J. G. Delcros, J. Biggerstaff, and O. Phanstiel, IV. 2003. Synthesis and biological evaluation of N1-(anthracen-9-ylmethyl)triamines as molecular recognition elements for the polyamine transporter. J. Med. Chem. 46:2663-2671.
45. Wang, C., J. G. Delcros, L. Cannon, F. Konate, H. Carias, J. Biggerstaff, R. A. Gardner, and O. Phanstiel, IV. 2003. Defining the molecular requirements for the selective delivery of polyamine conjugates into cells containing active polyamine transporters. J. Med. Chem. 46:5129-5138.
46. Weeks, R. S., S. M. Vanderwerf, C. L. Carlson, M. R. Burns, C. L. O'Day, F. Cai, B. H. Devens, and H. K. Webb. 2000. Novel lysine-spermine conjugate inhibits polyamine transport and inhibits cell growth when given with DFMO. Exp. Cell Res. 261:293-302.
47. Yarlett, N., and C. J. Bacchi. 1988. Effect of DL-alpha- difluoromethylornithine on polyamine synthesis and interconversion in Trichomonas vaginalis grown in a semi-defined medium. Mol. Biochem. Parasitol. 31:1-9.